Methylphenidate, Bupropion, and SSRI Triple Therapy

Authors

William Bobo M.D., National Capital Cosortium Military Psychiatry Residency - National Naval Medical Center, Walter Reed Army Medical Center

Abstract

Methylphenidate and bupropion have been demonstrated as being effective adjuncts to serotonin reuptake inhibitors in the treatment of depression (1,2). The use of these medications in case of a depressed patient whose condition was resistant to several forms of monotherapy, monotherapy with "standard" augmentation and ECT. After only a partial response to fluoxetine and methylphenidate, bupropion was added, resulting in full, sustained remission.

Recommended Citation

Bobo, William M.D. (2001) "Methylphenidate, Bupropion, and SSRI Triple Therapy," Jefferson Journal of Psychiatry: Vol. 16: Iss. 1, Article 8.
DOI: https://doi.org/10.29046/JJP.016.1.007
Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol16/iss1/8